The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Rozados, Viviana R.
dc.contributor.author Mainetti, Leandro Ernesto
dc.contributor.author Rico, María José
dc.contributor.author Zacarías Fluck, Mariano
dc.contributor.author Matar, Pablo
dc.contributor.author Scharovsky, O. Graciela
dc.date.accessioned 2012-08-27T15:00:48Z
dc.date.available 2012-08-27T15:00:48Z
dc.date.issued 2010-11-01
dc.identifier.citation Rozados, V. R., Mainetti, L. E., Rico, M. J., Zacarias, F. M. F., Matar, P., & Scharovsky, O. G. (September 27, 2010). The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncology Research, 18, 601-605. DOI: 10.3727/096504010X12777678141662 es
dc.identifier.issn 1555-3906
dc.identifier.uri http://hdl.handle.net/2133/2011
dc.description.abstract Metronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment endowed with an antiangiogenic effect. It refers to regular administration of low doses of cytotoxic drugs, with minimal or no drug-free breaks. Previously, we demonstrated the immunomodulating activity of a single low-dose of cyclophosphamide (Cy) and the antitumor effect of MCT with Cy on established rat lymphomas and sarcomas. Here, we examined whether the immune response is responsible for the antitumor effect of MCT with Cy on L-TACB lymphoma. Inbred e rats and nude mice were subcutaneously challenged with L-TACB. After 7 days, they were distributed into two experimental groups: 1) treated animals, which were injected IP with Cy (10 mg/kg body weight) three times per week, and 2) control animals, which received IP saline injections. Exponential growth and decay and tumor doubling time were calculated. Also, serum IL-10 levels were measured. One hundred percent of treated rats showed tumor regression versus 0% of control rats. The increase of tumor-induced IL-10 levels was reverted by the treatment with Cy. On the other hand, there were no tumor regressions, in treated or control nude mice. However, the tumor doubling times of treated nude mice were significantly higher than those of control mice, implying that other antitumor mechanism(s), independent of the adaptive immune response, might be taking place. Our present results indicate that modulation of the immune response would be involved in the antitumor effect of MCT with Cy, because the absence of the specific immune response impairs, at least in part, its therapeutic effect in a lymphoma tumor model. es
dc.description.sponsorship Universidad Nacional de Rosario es
dc.format application/pdf
dc.language.iso en es
dc.publisher Cognizant Communication Corporation es
dc.rights openAccess
dc.subject Metronomic chemotherapy es
dc.subject Immune response es
dc.subject Lymphoma es
dc.subject Cyclophosphamide es
dc.subject.mesh Antineoplastic Agents, Alkylating/therapeutic use
dc.subject.mesh Cyclophosphamide/therapeutic use
dc.subject.mesh Interleukin-10/blood
dc.subject.mesh Lymphoma/drug therapy
dc.subject.mesh Lymphoma/immunology
dc.title The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide es
dc.type article
dc.type artículo
dc.type publishedVersion
dc.identifier.doi http://dx.doi.org/10.3727/096504010X12777678141662
dc.description.peerreviewed Peer reviewed es
dc.relation.publisherversion http://dx.doi.org/10.3727/096504010X12777678141662 es
dc.rights.text © 2010 Cognizant Comm. Corp. es


Files in this item

This item appears in the following Collection(s)

Show simple item record

My Account


Search DSpace


Browse

Statistics